ProCE Banner Activity

Pooled Analysis of PhaseED-Seq MRD-Negativity Assessment as Surrogate Endpoint After Frontline Induction Therapy in Patients With DLBCL

Slideset Download
Conference Coverage

In patients with DLBCL, MRD status by PhaseED-Seq was strongly prognostic of PFS, particularly at end of induction therapy.

Released: December 13, 2022

Expiration: December 12, 2023

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen